Article
Clinical Neurology
R. Balestrino, T. Martone, M. Toffoli, E. Montanaro, M. Fabbri, C. A. Artusi, A. Romagnolo, M. Zibetti, M. Rizzone, S. Goldwurm, L. Lopiano, A. H. V. Schapira
Summary: This study analyzed the genetic mutations of 56 LCIG patients and retrospectively analyzed their motor and neuropsychological outcomes. The results showed no significant differences in motor or neuropsychological outcomes between patients with and without gene mutations/variants. PD patients with GBA mutations responded well to LCIG treatment in terms of motor symptoms.
NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Matthew Rosebraugh, Sven Stodtmann, Wei Liu, Maurizio F. Facheris
Summary: This study compares the pharmacokinetics of levodopa from subcutaneous infusion and levodopa carbidopa intestinal gel, and finds similar exposures.
PARKINSONISM & RELATED DISORDERS
(2022)
Article
Health Care Sciences & Services
Goekce Kilincalp, Anne-Christine Sjoestroem, Barbro Eriksson, Bjoern Holmberg, Radu Constantinescu, Filip Bergquist
Summary: The use of Parkinson Kinetigraph (PKG) can predict the response of Parkinson's disease patients to intestinal levodopa/carbidopa gel infusion (LCIG). If "off" periods cannot be clearly observed in the PKG, the treatment effect may be poorer, indicating the need for noninvasive infusion evaluation before surgery.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Clinical Neurology
Francesca Morgante, Valentina Oppo, Margherita Fabbri, Enrica Olivola, Chiara Sorbera, Rosa De Micco, Giovanna Chiara Ielo, Fabiana Colucci, Salvatore Bonvegna, Alessio Novelli, Nicola Modugno, Mariachiara Sensi, Maurizio Zibetti, Leonardo Lopiano, Alessandro Tessitore, Manuela Pilleri, Roberto Cilia, Antonio E. Elia, Roberto Eleopra, Lucia Ricciardi, Giovanni Cossu
Summary: The study showed that LCIG infusion can be effective for late elderly Parkinson's disease patients, with no significant differences in quality of life, motor and non-motor symptoms severity, side effects, and dropout rates compared to younger patients.
JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Alfonso Fasano, Tanya Gurevich, Robert Jech, Norbert Kovacs, Per Svenningsson, Jozsef Szasz, Juan Carlos Parra, Lars Bergmann, Anita Johnson, Olga Sanchez-Solino, Zhongwen Tang, Lydia Vela-Desojo
Summary: LCIG is an effective long-term monotherapy option for the treatment of advanced Parkinson's disease, contributing to reduced polypharmacy and offering a positive risk-benefit profile.
MOVEMENT DISORDERS
(2021)
Article
Clinical Neurology
Peter A. LeWitt, Fabrizio Stocchi, David Arkadir, Yoseph Caraco, Liat Adar, Itay Perlstein, Ryan Case, Nir Giladi
Summary: Continuous subcutaneous infusion of ND0612 provides stable and sustained plasma concentrations of levodopa, avoiding troughs in levodopa plasma concentrations associated with off time in Parkinson's disease. This delivery system has the potential to be a convenient and well-tolerated option for PD patients experiencing motor fluctuations.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Sandeep Thakkar, Victor S. C. Fung, Aristide Merola, Meredith Rollins, Michael J. Soileau, Norbert Kovacs
Summary: The infusion of LCIG is a standard treatment for advanced Parkinson's disease, and extending it to 24 hours may further alleviate symptoms. However, studies on 24-hour infusion are limited by small sample sizes and study designs. Clinical experience suggests that some patients may benefit from 24-hour infusion, but dose adjustments and monitoring are necessary.
Review
Pharmacology & Pharmacy
Sheila A. Doggrell
Summary: Parkinson's disease (PD) is a common neurodegenerative disease and the standard treatment is oral medication. However, as the disease progresses, the effectiveness of oral medication decreases, leading to motor fluctuations and dyskinesia. This article discusses the development of subcutaneous preparations for the treatment of motor fluctuations in PD, which show promising results in reducing symptoms.
EXPERT OPINION ON DRUG DELIVERY
(2023)
Article
Clinical Neurology
Federica Garri, Francesco Paolo Russo, Tommaso Carrer, Luca Weis, Francesca Pistonesi, Michele Mainardi, Michele Sandre, Edoardo Savarino, Fabio Farinati, Francesca Del Sorbo, Paola Soliveri, Daniela Calandrella, Roberta Biundo, Miryam Carecchio, Anna Lena Zecchinelli, Gianni Pezzoli, Angelo Antonini
Summary: This study retrospectively analyzed the usage of LCIG in 79 patients with Parkinson's disease and found that it has a relatively satisfactory long-term safety profile and efficacy, with a low rate of discontinuation. Peristomal complications may be a predictor of longer duration of therapy.
JOURNAL OF NEUROLOGY
(2022)
Review
Clinical Neurology
Taiji Tsunemi, Genko Oyama, Shinji Saiki, Taku Hatano, Jiro Fukae, Yasushi Shimo, Nobutaka Hattori
Summary: LCIG treatment shows significant efficacy in reducing OFF time, increasing ON time, and improving some nonmotor symptoms and quality of life in Parkinson's disease patients. Discontinuation rates are mainly related to device issues, but the convenience of discontinuation with LCIG may be an advantage.
MOVEMENT DISORDERS
(2021)
Review
Clinical Neurology
Dag Nyholm, Wolfgang H. Jost
Summary: As Parkinson's disease progresses, treatment needs to be adjusted to maintain symptom control. Device-aided therapy, such as levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion, can provide continuous dopaminergic stimulation for patients with advanced PD. LECIG infusion has been shown to be clinically effective, with similar motor function improvement as standard levodopa-carbidopa intestinal gel (LCIG) infusion, but at lower overall levodopa doses. Real-world data will continue to be collected to establish the long-term efficacy and safety of LECIG infusion.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2022)
Article
Clinical Neurology
Eric Freire-Alvarez, Egon Kurca, Lydia Lopez Manzanares, Eero Pekkonen, Cleanthe Spanaki, Paola Vanni, Yang Liu, Olga Sanchez-Solino, Luigi M. Barbato
Summary: The study showed that LCIG significantly reduced dyskinesia compared to oral optimized medical treatment, and also demonstrated significant improvements in quality of life and activities of daily living in patients with advanced Parkinson's disease.
MOVEMENT DISORDERS
(2021)
Article
Clinical Neurology
Marta Melis, Sarah Vascellari, Maria Laura Santoru, Valentina Oppo, Margherita Fabbri, Marianna Sarchioto, Daniela Murgia, Maurizio Zibetti, Leonardo Lopiano, Alessandra Serra, Vanessa Palmas, Silvia Pisanu, Daniela Perra, Veronica Madau, Roberto Cusano, Paolo Uva, Alessandra Mereu, Paolo Contu, Micaela Morelli, Luigi Atzori, Maurizio Melis, Aldo Manzin, Giovanni Cossu
Summary: The study suggests that levodopa and levodopa-carbidopa intestinal gel may significantly influence the composition of gut microbiota and host/bacteria metabolism in Parkinson's disease patients, potentially leading to a specific inflammatory intestinal microenvironment.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Neurosciences
Matthew Rosebraugh, Wei Liu, Melina Neenan, Maurizio F. Facheris
Summary: Foslevodopa/foscarbidopa demonstrated stable LD and CD exposures in PD patients over 72 hours via SC route, with minimal fluctuations. This infusion method showed favorable safety and tolerability profiles in treating aPD patients.
JOURNAL OF PARKINSONS DISEASE
(2021)
Article
Medicine, Research & Experimental
Yusuke Nomoto, Makoto Furihata, Haruka Hagiwara, Hirotaka Ishino, Shintaro Yano, Hiroki Okawa, Yoichi Nakatsu, Kumiko Noda, Shinjiro Nishi, Shingo Ogiwara, Tsuneo Kitamura, Taro Osada
Summary: This study evaluated the efficacy and safety of transgastric jejunostomy (PEG-J) as a delivery method for levodopa-carbidopa intestinal gel (LCIG) in Parkinson's disease patients. The results showed that PEG-J for LCIG infusion significantly improved motor symptoms, reduced motor fluctuations, and enhanced quality of life. This method allowed for precise and continuous delivery of LCIG, ensuring consistent therapeutic levels with low complications.
MEDICAL SCIENCE MONITOR
(2023)
Editorial Material
Clinical Neurology
Philippe Salles, Hubert H. Fernandez
PARKINSONISM & RELATED DISORDERS
(2020)
Review
Clinical Neurology
Pedro Chana-Cuevas, Philippe Salles-Gandara, Alejandro Rojas-Fernandez, Constanza Salinas-Rebolledo, Anna Milan-Sole
FRONTIERS IN NEUROLOGY
(2020)
Review
Clinical Neurology
James Y. Liao, Philippe A. Salles, Umar A. Shuaib, Hubert H. Fernandez
Summary: Paroxysmal dyskinesias are a diverse group of genetic disorders characterized by episodic movements, specific triggers, attack frequency, and duration. Advances in genetic sequencing have led to a significant increase in the number of genetic variants associated with paroxysmal dyskinesia, revealing genotype-phenotype overlap, reduced penetrance, and phenotypic variability. Collaboration between basic scientists, geneticists, and clinicians is essential to effectively diagnose and treat patients with paroxysmal dyskinesias.
JOURNAL OF NEURAL TRANSMISSION
(2021)
Review
Clinical Neurology
Philippe A. Salles, Ignacio F. Mata, Tobias Bruenger, Dennis Lal, Hubert H. Fernandez
Summary: The Na+/K+ ATPases are a critical part of cell membrane function, with the ATP1A3 gene encoding the α 3 isoform which is associated with neurological disorders. Pathogenic variants in this gene can lead to a range of symptoms, often presenting with acute onset and triggered episodes by fever or other factors.
FRONTIERS IN NEUROLOGY
(2021)
Correction
Clinical Neurology
James Y. Liao, Philippe A. Salles, Umar A. Shuaib, Hubert H. Fernandez
JOURNAL OF NEURAL TRANSMISSION
(2022)
Editorial Material
Clinical Neurology
A. Philippe Salles
PARKINSONISM & RELATED DISORDERS
(2021)
Article
Clinical Neurology
Philippe A. Salles, Alberto J. Espay
Summary: In this case study, a young man with HIV and syphilis developed right-hand epilepsia partialis continua associated with a small frontal lesion. 'Mechanographic' data from a pen and paper test helped differentiate the condition from other causes of low-frequency repetitive hand movements.
PRACTICAL NEUROLOGY
(2021)
Meeting Abstract
Clinical Neurology
Umar A. Shuaib, Lauren M. Boyd, James Morrison, Philippe A. Salles, James Liao, Hubert H. Fernandez, Xin Xin Yu
ANNALS OF NEUROLOGY
(2021)
Meeting Abstract
Clinical Neurology
P. Salles, I. Mata, H. Fernandez
PARKINSONISM & RELATED DISORDERS
(2020)
Meeting Abstract
Clinical Neurology
P. Salles, M. Sy, H. Fernandez, M. Gostkowski
PARKINSONISM & RELATED DISORDERS
(2020)
Article
Medicine, General & Internal
Philippe Salles Gandara, Pedro Chana-Cuevas
REVISTA MEDICA DE CHILE
(2020)
Article
Clinical Neurology
Jun-Pyo Hong, Hanim Kwon, Euyhyun Park, Sun-Uk Lee, Chan-Nyoung Lee, Byung-Jo Kim, Ji-Soo Kim, Kun-Woo Park
Summary: In patients with mild-to-moderate PD, vestibular function assessed by video head-impulse tests appears relatively preserved and has minimal impact on the risk of falls. Risk of postural instability is associated with the severity of clinical symptoms in PD.
PARKINSONISM & RELATED DISORDERS
(2024)
Article
Clinical Neurology
Yaqin Xiang, XiuRong Huang, Qian Xu, Zhenhua Liu, Yase Chen, Qiying Sun, Junling Wang, Hong Jiang, Lu Shen, Xinxiang Yan, Beisha Tang, Jifeng Guo
Summary: Using the novel data-driven method DEBM, this study determined the sequence of several common biomarker changes in Parkinson's disease (PD). The left putamen was found to be the earliest biomarker to become abnormal, followed by the right putamen, CSF alpha-synuclein, right caudate, left caudate, and serum NfL. The estimated disease stages showed significant differences between PD and healthy controls, and achieved a high accuracy for distinguishing PD from HC.
PARKINSONISM & RELATED DISORDERS
(2024)
Article
Clinical Neurology
Yan Li, David J. McLernon, Carl E. Counsell, Angus D. Macleod
Summary: This study aimed to investigate the incidence and risk factors for institutionalisation in Parkinson's disease (PD) and atypical parkinsonism (AP). The study found that institutionalisation was more frequent in AP compared to PD and controls. Age, poorer cognition, and more-severe parkinsonian impairment were independent predictors of institutionalisation.
PARKINSONISM & RELATED DISORDERS
(2024)